Statins as primary prevention in patients without dyslipidaemia

نویسندگان

  • Luke Bereznicki
  • Leanne Stafford
چکیده

Mr VW is a 52-year-old regular customer of your pharmacy. He is not overweight, runs 10km three times a week, eats healthily, does not smoke and controls his hypertension with quinapril (Accupril) 10mg daily. He was recently shocked when his 53-year-old long-time friend suffered a massive heart attack while playing golf at the local country club and died before the ambulance arrived, so he underwent a full medical check-up and was given a clean bill of health, Although his GP has assured him that his cholesterol levels are completely normal, his wife has 'read somewhere that he perhaps should have another blood test and be taking a statin medication anyway'.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

As part of its single technology appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical and cost effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in combination with a statin with or without ezetimibe, or in combination with ezetimibe (without stati...

متن کامل

Statin diabetogenicity: guidance for clinicians

Type 2 diabetes (T2D) is a strong, independent risk factor for cardiovascular (CV) and cerebrovascular outcomes. Meta-analysis of five randomised clinical trials (n = 33,040) showed that, although intensive versus standard glycaemic control significantly reduced CV events in people with T2D, the reduction was less than that achieved with lipid-lowering or antihypertensive treatment. Furthermore...

متن کامل

Cardiovascular risk prediction: balancing complexity against simple practicality.

significant decline in cardiovascular mortality and morbidity has been achieved with the improvements in detection and prevention programmes for major risk factors (such as smoking, low physical activity levels, obesity, and high blood pressure) related to cardiovascular disease (CVD). However, CVD still remains the leading cause of mortality and disability in the world. Collectively, ischaemic...

متن کامل

Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly referred to as statins, are widely used in the treatment of dyslipidaemia, in addition to providing primary and secondary prevention against cardiovascular disease and stroke. Statins' effects on the central nervous system (CNS), particularly on cognition and neurological disorders such as stroke and multiple sclerosis, have r...

متن کامل

Statins for Renal Patients: A Fiddler on the Roof?

Atherosclerotic cardiovascular disease is the main cause of morbidity and mortality in chronic kidney disease patients. There is a raft of evidence showing that in the general population dyslipidaemia is associated with an increased risk of cardiovascular events, as well as with a greater prevalence of chronic kidney disease. Consequently, the use of statins in the general population with dysli...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2009